486 related articles for article (PubMed ID: 37542343)
41. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
42. Recent technologies enhancing the clinical utility of circulating tumor DNA.
Manoharan A; Sambandam R; Bhat V
Clin Chim Acta; 2020 Nov; 510():498-506. PubMed ID: 32795543
[TBL] [Abstract][Full Text] [Related]
43. Liquid Biopsy: Current Status and Future Perspectives.
Mader S; Pantel K
Oncol Res Treat; 2017; 40(7-8):404-408. PubMed ID: 28693023
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
45. Potential clinical utility of liquid biopsies in ovarian cancer.
Zhu JW; Charkhchi P; Akbari MR
Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
[TBL] [Abstract][Full Text] [Related]
46. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.
Normanno N; Cervantes A; Ciardiello F; De Luca A; Pinto C
Cancer Treat Rev; 2018 Nov; 70():1-8. PubMed ID: 30053724
[TBL] [Abstract][Full Text] [Related]
47. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
48. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.
Raza A; Khan AQ; Inchakalody VP; Mestiri S; Yoosuf ZSKM; Bedhiafi T; El-Ella DMA; Taib N; Hydrose S; Akbar S; Fernandes Q; Al-Zaidan L; Krishnankutty R; Merhi M; Uddin S; Dermime S
J Exp Clin Cancer Res; 2022 Mar; 41(1):99. PubMed ID: 35292091
[TBL] [Abstract][Full Text] [Related]
49. Molecular Profiling of Liquid Biopsies for Precision Oncology.
Gonzalez-Kozlova EE
Adv Exp Med Biol; 2022; 1361():235-247. PubMed ID: 35230692
[TBL] [Abstract][Full Text] [Related]
50. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.
Romero A; Serna-Blasco R; Calvo V; Provencio M
Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428
[TBL] [Abstract][Full Text] [Related]
51. A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance.
Nicolazzo C; Gazzaniga P
Methods Mol Biol; 2022; 2535():93-104. PubMed ID: 35867225
[TBL] [Abstract][Full Text] [Related]
52. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
53. Circulating tumor DNA and liquid biopsy in oncology.
Cescon DW; Bratman SV; Chan SM; Siu LL
Nat Cancer; 2020 Mar; 1(3):276-290. PubMed ID: 35122035
[TBL] [Abstract][Full Text] [Related]
54. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
Petrillo A; Salati M; Trapani D; Ghidini M
Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
[TBL] [Abstract][Full Text] [Related]
55. Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.
Verbanac D; Čeri A; Hlapčić I; Shakibaei M; Brockmueller A; Krušlin B; Ljubičić N; Baršić N; Detel D; Batičić L; Rumora L; Somborac-Bačura A; Štefanović M; Ćelap I; Demirović A; Petlevski R; Petrik J; Grdić Rajković M; Hulina-Tomašković A; Rako I; Saso L; Barišić K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919272
[TBL] [Abstract][Full Text] [Related]
56. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples.
Russano M; Napolitano A; Ribelli G; Iuliani M; Simonetti S; Citarella F; Pantano F; Dell'Aquila E; Anesi C; Silvestris N; Argentiero A; Solimando AG; Vincenzi B; Tonini G; Santini D
J Exp Clin Cancer Res; 2020 May; 39(1):95. PubMed ID: 32460897
[TBL] [Abstract][Full Text] [Related]
57. Liquid biopsy = Individualized cancer management: Diagnosis, monitoring treatment and checking recurrence and metastasis.
Mali SB; Dahivelkar S
Oral Oncol; 2021 Dec; 123():105588. PubMed ID: 34744021
[TBL] [Abstract][Full Text] [Related]
58. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
59. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
Lyu X; Tsui YM; Ho DW; Ng IO
Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
[TBL] [Abstract][Full Text] [Related]
60. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
